Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call indicates strong financial performance with raised guidance, significant market expansion, and operational efficiency gains. AI initiatives and new product developments bolster the outlook. The Q&A session reveals positive sentiment towards growth in key markets and effective strategies for TAM expansion. Despite some uncertainties in long-term revenue impacts, the overall narrative is optimistic, suggesting a stock price increase in the near term.
Q4 Revenue $171 million, representing 46% year-over-year growth. The increase was driven by strong demand for Hinge Health's services.
Full Year 2025 Revenue $588 million, up 51% compared to 2024. This growth reflects the growing demand for Hinge Health's offerings.
Last 12 Months Calculated Billings $671 million, up 44% compared to the same period in 2024. This indicates strong client engagement and adoption.
Q4 Gross Margin 85%, reflecting scalability of the technology-driven care model.
Full Year 2025 Gross Margin 83%, demonstrating operational efficiency and scalability.
Q4 Operating Margin 28%, showing the impact of investments in automation and operational efficiency.
Full Year 2025 Operating Margin 20%, reflecting progress towards the target of 25%+ operating margin.
Q4 Free Cash Flow $62 million, representing a free cash flow margin of 36%. This was driven by operational efficiency and strong revenue growth.
Full Year 2025 Free Cash Flow $180 million, with an annual free cash flow margin of 31%. This achievement was ahead of the IPO target.
Rule of 40 Metric 81% for the full year and 82% in Q4, significantly exceeding the standard of 40. This reflects the combination of revenue growth and free cash flow margin.
Net Dollar Retention Well above 110% for 2025, driven by high client retention and yield improvements.
Q4 Income from Operations $48 million, with an operating margin of 28%, up from 18% in Q4 2024.
Full Year 2025 Income from Operations $119 million, with an operating margin of 20%, a significant improvement from negative 7% in 2024.
Q4 Diluted Net Income Per Share $0.49, highlighting the earnings power of the business.
AI-powered tools: Rolled out improvements that help clinicians work more effectively and handle more members without compromising care quality. Automated AI-powered communications for routine messaging were introduced, leading to a 28% reduction in care team time spent in asynchronous sessions from Q3 to Q4 2025. Robin, the AI care assistant, received a 92% positive rating from members.
HingeSelect: Launched a high-performance provider network available to several hundred thousand eligible lives in Q4. Early data shows 85% of members moved forward with conservative care plans, often digital physical therapy, reducing low-value spend like imaging and surgeries.
Contracted Lives: Added 4.8 million net new contracted lives in 2025, ending the year with 24.6 million contracted lives, a 25% year-over-year growth. Significant growth in fully insured Medicare Advantage and federal employee programs.
Client Base: Clients now represent 53% of the Fortune 100 and 45% of the Fortune 500, showcasing trust from leading organizations.
Revenue Growth: Q4 revenue reached $171 million, a 46% year-over-year growth. Full-year 2025 revenue was $588 million, up 51% from 2024.
Operational Efficiency: Gross margin was 85% in Q4 and 83% for the full year 2025. Operating margin reached 28% in Q4 and 20% for the full year. Free cash flow margin was 36% in Q4 and 31% for the full year.
AI and Automation: Investments in AI-powered tools and automation have significantly improved care delivery efficiency and member satisfaction.
HingeSelect Expansion: Building a two-sided marketplace with high-quality providers, expected to become a competitive advantage by 2027.
Regulatory Risks: The company operates in a highly regulated space, and any changes in regulations or failure to comply with existing regulations could adversely impact operations and financial performance.
Market Competition: The company faces competitive pressures, including the risk of losing clients to competitors or failing to attract new clients in a highly competitive market.
Supply Chain and Network Expansion: Building and scaling the HingeSelect provider network is a long-term effort that may face challenges, including delays or difficulties in creating a two-sided marketplace.
Economic Uncertainty: Economic downturns or uncertainties could impact the company's ability to attract and retain clients, particularly in the self-insured and Medicare Advantage segments.
Strategic Execution Risks: The company is making significant investments in AI and new product initiatives, which may not yield the expected returns or could face implementation challenges.
Client Retention and Yield: While client retention is high, any decline in retention rates or failure to improve yield could negatively impact financial performance.
Pricing Model Transition: The transition to an engagement-based pricing model could pose risks if not managed effectively, potentially impacting revenue.
Technology and Data Risks: Reliance on AI-powered tools and proprietary data introduces risks related to data security, privacy, and potential technological failures.
Revenue Projections for 2026: Hinge Health expects revenue to be in the range of $732 million to $742 million for the full year 2026, representing 25% year-over-year growth at the midpoint.
Q1 2026 Revenue Guidance: Revenue is projected to be in the range of $171 million to $173 million, representing 39% year-over-year growth at the midpoint.
Operating Margin for 2026: Non-GAAP income from operations is expected to be $151 million to $156 million, representing a 21% margin at the midpoint, which is a 100 basis point improvement over 2025.
Gross Margin Outlook: Gross margin is anticipated to improve by approximately 100 basis points in 2026 over 2025, driven by AI efficiency tools, though offset by broader Enso deployments.
Member Base Growth: Average LTM eligible lives for full year 2026 are expected to be 24.4 million lives, with growth driven by new lives already won.
Yield and Pricing Expectations: Yield is expected to remain flat in 2026, with a clear roadmap for incremental improvements over time. Average selling price is also expected to stay flat.
AI and Efficiency Investments: Hinge Health plans to keep the care team size flat in 2026, leveraging AI-powered tools to improve efficiency and member experience. Investments will focus on research and development and sales and marketing to support HingeSelect expansion and growth in small and medium business markets.
HingeSelect Revenue Impact: HingeSelect is not expected to have a significant revenue impact until at least 2027, but it is anticipated to become a major competitive advantage once scaled.
GAAP Profitability: Hinge Health expects to be GAAP profitable in 2026, continuing the trend from Q4 2025.
Share Repurchase Program: In November, the Board authorized a share repurchase program of up to $250 million. In Q4, the company repurchased 1.4 million shares for $65 million. The program is expected to be executed as market conditions warrant.
The earnings call indicates strong financial performance with raised guidance, significant market expansion, and operational efficiency gains. AI initiatives and new product developments bolster the outlook. The Q&A session reveals positive sentiment towards growth in key markets and effective strategies for TAM expansion. Despite some uncertainties in long-term revenue impacts, the overall narrative is optimistic, suggesting a stock price increase in the near term.
The earnings call summary and Q&A indicate strong operational efficiency through AI, robust cash flow, and strategic enrollment initiatives. Despite some unclear responses, the company shows positive yield improvements and a growing pipeline. The federal shutdown has had no impact, and the company is addressing cost pressures effectively. Overall, these factors suggest a positive market reaction.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.